---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016511"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:31:22.331433+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix reports Q1 net loss $4.45M; cash runway extended to Q4 2024

## Summary
- Net loss of $4.45M ($1.22 per share) vs $4.97M loss in Q1 2022.
- Revenue $1.5M, up from $1.2M, mainly from Cipla agreement.
- Cash $30.8M; projected runway extended from Q2 2024 to Q4 2024.
- Phase 2b PUR1900 trial dosing initiated for ABPA; topline data expected mid-2024.
- Phase 1 PUR3100 migraine study positive; IND filing planned mid-2023, Phase 2 pending financing.

## SEC filing metadata
- accession: 0001493152-23-016511
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/0001493152-23-016511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016511
- JSON: https://secwatch.observer/filing/0001493152-23-016511.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016511.txt

## Key facts
- Earnings Releases
  Pulmatrix, Inc. reported the three months ended March 31, 2023 results: revenue $1.5 million.
  - Period: the three months ended March 31, 2023
  - Revenue: $1.5 million
  - Result: reported results
  source text: Revenues increased $0.3 million to $1.5 million for the three months ended March 31, 2023 compared to $1.2 million for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/0001493152-23-016511-index.htm
- Earnings Releases
  Pulmatrix, Inc. reported financial results for the first fiscal quarter ended March 31, 2023.
  - Period: the first fiscal quarter ended March 31, 2023
  - Result: reported results
  source text: On May 12, 2023, Pulmatrix, Inc. (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2023 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/0001493152-23-016511-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.